STVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stevanato Group SpA (STVN) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical analysis indicates a bearish trend, and there are no significant positive catalysts or trading signals to support immediate action. While the company has shown some revenue growth, declining net income and EPS, along with mixed analyst sentiment, suggest a cautious approach. Holding off for a better entry point or more positive indicators is recommended.
The technical indicators for STVN show a bearish trend. The MACD is negatively expanding, RSI is neutral at 22.027, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Current price is below the key pivot level of 14.686, with support at 13.849 and resistance at 15.523.
NULL identified. No significant news or events in the past week. The company benefits from structural shifts toward biologics, but this is a long-term driver rather than an immediate catalyst.
Bearish technical indicators, declining net income (-1.57% YoY) and EPS (-5.56% YoY) in the latest quarter, and mixed analyst ratings with multiple price target reductions. No recent insider or hedge fund activity to indicate strong sentiment.
In Q4 2025, revenue increased by 4.81% YoY to $346.48M. However, net income dropped by 1.57% YoY to $47.55M, and EPS declined by 5.56% YoY to $0.17. Gross margin improved slightly to 31.81%, up 3.45% YoY.
Analyst sentiment is mixed. Morgan Stanley maintains an Equal Weight rating with a reduced price target of $19. Citi and BofA maintain Buy ratings with reduced price targets of $26 and $28, respectively. KeyBanc highlights strong GLP-1 revenue growth but notes a shift in focus to the core biologics business. Jefferies maintains a Hold rating with a reduced price target of $17.50, citing headwinds in injectable packaging.
